Pharmacovigilance – Products

The interactions between FcRn and IgG are strongly associated with the development of antibody drugs and targeting FcRn presents an effective therapeutic strategy to reduce serum IgG levels in autoimmune diseases. Using the FcRn Binding Kit (TR-FRET): unleashing the potential of high-throughput antibody drug screening, enabling rapid progress in your research endeavors.

Just – Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD’s Manufacturing Optimization Program.

Ascelia Pharma AB (publ) (ticker: ACE), announced that liver imaging drug candidate, Orviglance®, significantly improved visualization of focal liver lesions, successfully meeting the primary endpoint in the pivotal Phase 3 study SPARKLE.

Ready-to-use kit expands range of bioanalysis kits, and enables generic detection of immune complexes in rodent samples.

To drive the advancement of your antibody drug innovation and development, we offer comprehensive solutions including: target proteins, Fc receptor proteins, kits, beads and services, etc.

Optimer delivery vehicle has been shipped to a pharma partner for external evaluation. The specific delivery vehicle could generate new precision therapies for liver disease.

AMSBIO reports that its extensive range of FDA tissue microarrays reliably enhances tissue cross-reactivity (TCR) and other target validation studies.

As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma (R/R FL), glofitamab (Columvi) for relapsed or refractory diffuse B cell lymphoma

resDetect™ is a series of reagent kits designed to follow international legal and regulatory requirements and guidelines for the detection of residual components in the biopharmaceutical manufacturing process.

ProBioGen, is pleased to announce the execution of services and license agreements with MAPP BIOPHARMACEUTICAL, INC. to develop a cell line for an afucosylated antibody targeting Marburg virus (MARV) infection.